home / stock / hnsbf / hnsbf short
Short Information | Hansa Biopharma AB (OTCMKTS:HNSBF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 38,742 |
Total Actual Volume | 54,492 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 19 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,937 |
Average Short Percentage | 94.58% |
Is there a HNSBF Short Squeeze or Breakout about to happen?
See the HNSBF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
03-14-2024 | $2.93 | $2.93 | $2.93 | $2.93 | 150 | 150 | 100% |
01-29-2024 | $3.22 | $3.3 | $3.3 | $3.22 | 200 | 200 | 100% |
12-19-2023 | $2.257 | $2.257 | $2.257 | $2.257 | 700 | 700 | 100% |
09-05-2023 | $3.93 | $3.93 | $3.93 | $3.93 | 130 | 130 | 100% |
07-31-2023 | $4.755 | $4.755 | $4.755 | $4.755 | 1,000 | 1,000 | 100% |
07-27-2023 | $0 | $5.295 | $0 | $0 | 40 | 40 | 100% |
07-18-2023 | $0 | $5.295 | $0 | $0 | 2 | 2 | 100% |
03-08-2023 | $0 | $5.2 | $0 | $0 | 30 | 30 | 100% |
02-01-2023 | $5.92 | $5.92 | $5.92 | $5.92 | 240 | 240 | 100% |
01-24-2023 | $6.65 | $6.6 | $6.65 | $6.6 | 3,000 | 1,250 | 41.67% |
08-25-2022 | $0 | $5.66 | $0 | $0 | 8,000 | 8,000 | 100% |
12-02-2021 | $10.1 | $10.1 | $10.1 | $10.1 | 900 | 900 | 100% |
06-29-2021 | $18.2 | $18.2 | $18.2 | $18.2 | 1,000 | 1,000 | 100% |
11-03-2020 | $29.5 | $29.5 | $29.5 | $29.5 | 200 | 200 | 100% |
10-13-2020 | $28.03 | $28.03 | $28.03 | $28.03 | 200 | 200 | 100% |
10-07-2020 | $28.9 | $28.9 | $28.9 | $28.9 | 10,000 | 10,000 | 100% |
07-27-2020 | $28.65 | $28.65 | $28.65 | $28.65 | 28,000 | 14,000 | 50% |
09-30-2019 | $13.30 | $13.30 | $13.30 | $13.30 | 300 | 300 | 100% |
09-25-2019 | $13.60 | $13.60 | $13.60 | $13.60 | 300 | 300 | 100% |
09-12-2019 | $15.70 | $15.70 | $15.70 | $15.70 | 100 | 100 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Hansa Biopharma AB Company Name:
HNSBF Stock Symbol:
OTCMKTS Market:
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation PR Newswire Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared ...
Hansa Biopharma interim report January-March 2023 PR Newswire Positive reimbursement decision in Spain expands market access to include the five largest European markets Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed HNSA-...
The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...